• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer.

作者信息

Watanabe Satomi, Takeda Masayuki, Otani Tomoyuki, Yoshida Takeshi, Sakai Kazuko, Olek Elizabeth, Rothenberg S Michael, Kherani Jennifer, French Pearl P, Nishio Kazuto, Ito Akihiko, Nakagawa Kazuhiko

机构信息

Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

Department of Pathology, Kindai University Faculty of Medicine, Osaka-Sayama, Osaka, Japan.

出版信息

JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00282. eCollection 2021.

DOI:10.1200/PO.20.00282
PMID:34036231
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8140803/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/547d/8140803/7fd9945fa1ac/po-5-po.20.00282-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/547d/8140803/ab344205de24/po-5-po.20.00282-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/547d/8140803/7fd9945fa1ac/po-5-po.20.00282-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/547d/8140803/ab344205de24/po-5-po.20.00282-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/547d/8140803/7fd9945fa1ac/po-5-po.20.00282-g002.jpg

相似文献

1
Complete Response to Selective RET Inhibition With Selpercatinib (LOXO-292) in a Patient With Fusion-Positive Breast Cancer.一名融合阳性乳腺癌患者对塞尔帕替尼（LOXO-292）选择性RET抑制的完全缓解。
JCO Precis Oncol. 2021 Jan 11;5. doi: 10.1200/PO.20.00282. eCollection 2021.
2
Response to the Selective RET Inhibitor Selpercatinib (LOXO-292) in a Patient With RET Fusion-positive Atypical Lung Carcinoid.RET融合阳性非典型肺类癌患者对选择性RET抑制剂塞尔帕替尼（LOXO-292）的反应
Clin Lung Cancer. 2021 May;22(3):e442-e445. doi: 10.1016/j.cllc.2020.06.011. Epub 2020 Jun 18.
3
Novel RET Fusion Predicts Response to Selective RET Inhibition With Selpercatinib in Malignant Pheochromocytoma.新型RET融合预测恶性嗜铬细胞瘤对塞普替尼选择性RET抑制的反应。
JCO Precis Oncol. 2021 Nov;5:1160-1165. doi: 10.1200/PO.21.00127.
4
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.塞尔帕替尼治疗融合阳性非小细胞肺癌的疗效
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
5
Efficacy of Selpercatinib in -Altered Thyroid Cancers.塞尔帕替尼在改变的甲状腺癌中的疗效。
N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.
6
Selpercatinib: First Approval.塞尔帕替尼：首次批准。
Drugs. 2020 Jul;80(11):1119-1124. doi: 10.1007/s40265-020-01343-7.
7
Intracranial Efficacy of Selpercatinib in Fusion-Positive Non-Small Cell Lung Cancers on the LIBRETTO-001 Trial.LIBRETTO-001 试验中融合阳性非小细胞肺癌患者中 Selpercatinib 的颅内疗效。
Clin Cancer Res. 2021 Aug 1;27(15):4160-4167. doi: 10.1158/1078-0432.CCR-21-0800. Epub 2021 Jun 4.
8
NTRK and RET fusion-directed therapy in pediatric thyroid cancer yields a tumor response and radioiodine uptake.NTRK 和 RET 融合导向治疗在儿科甲状腺癌中产生肿瘤反应和放射性碘摄取。
J Clin Invest. 2021 Sep 15;131(18). doi: 10.1172/JCI144847.
9
Selpercatinib.塞尔帕替尼
Am J Health Syst Pharm. 2020 Oct 30;77(22):1818-1821. doi: 10.1093/ajhp/zxaa279.
10
Rearranged-in-transfection inhibitors: emerging agnostic targeted therapies for solid tumors.转染重排抑制剂：实体瘤新兴的非特异性靶向治疗方法
Pharmacogenomics. 2021 Apr;22(5):247-250. doi: 10.2217/pgs-2021-0002. Epub 2021 Mar 23.

引用本文的文献

1
Case report: Eczematous adverse drug reaction after selpercatinib treatment.病例报告：塞尔帕替尼治疗后出现的湿疹样药物不良反应。
Front Oncol. 2024 Dec 24;14:1475541. doi: 10.3389/fonc.2024.1475541. eCollection 2024.
2
Evolution of treatment strategies for solid tumors with RET rearrangement in China and real-world treatment status of Non-small Cell Lung Cancer (NSCLC).中国具有 RET 重排的实体瘤治疗策略的演变和非小细胞肺癌（NSCLC）的真实世界治疗状况。
BMC Pulm Med. 2024 Nov 4;24(1):552. doi: 10.1186/s12890-024-03371-5.
3
REThinking the role of the RET oncogene in breast cancer.

本文引用的文献

1
Efficacy of Selpercatinib in -Altered Thyroid Cancers.塞尔帕替尼在改变的甲状腺癌中的疗效。
N Engl J Med. 2020 Aug 27;383(9):825-835. doi: 10.1056/NEJMoa2005651.
2
Efficacy of Selpercatinib in Fusion-Positive Non-Small-Cell Lung Cancer.塞尔帕替尼治疗融合阳性非小细胞肺癌的疗效
N Engl J Med. 2020 Aug 27;383(9):813-824. doi: 10.1056/NEJMoa2005653.
3
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update.乳腺癌中雌激素受体和孕激素受体检测：美国临床肿瘤学会/美国病理学家学院指南更新。
重新审视RET原癌基因在乳腺癌中的作用。
Front Oncol. 2024 Aug 1;14:1427228. doi: 10.3389/fonc.2024.1427228. eCollection 2024.
4
-Altered Cancers-A Tumor-Agnostic Review of Biology, Diagnosis and Targeted Therapy Activity.- 改变的癌症——肿瘤非特异性生物学、诊断及靶向治疗活性综述
Cancers (Basel). 2023 Aug 17;15(16):4146. doi: 10.3390/cancers15164146.
5
RET signaling in breast cancer therapeutic resistance and metastasis.RET 信号在乳腺癌治疗抵抗和转移中的作用。
Breast Cancer Res. 2023 Mar 14;25(1):26. doi: 10.1186/s13058-023-01622-7.
6
Advances in the Diagnosis and Treatment of a Driving Target: RET Rearrangements in non-Small-Cell Lung Cancer (NSCLC) Especially in China.驱动靶点的诊治进展：非小细胞肺癌（NSCLC）中 RET 重排，尤其是在中国。
Technol Cancer Res Treat. 2023 Jan-Dec;22:15330338221148802. doi: 10.1177/15330338221148802.
7
Novel Calcium-Binding Ablating Mutations Induce Constitutive RET Activity and Drive Tumorigenesis.新型钙结合消融突变诱导持续 RET 活性并驱动肿瘤发生。
Cancer Res. 2022 Oct 17;82(20):3751-3762. doi: 10.1158/0008-5472.CAN-22-0834.
8
Hallmarks of RET and Co-occuring Genomic Alterations in -aberrant Cancers.RET 基因改变与相关异常癌症的特征。
Mol Cancer Ther. 2021 Oct;20(10):1769-1776. doi: 10.1158/1535-7163.MCT-21-0329. Epub 2021 Sep 6.
9
Current Status of Next-Generation Sequencing-Based Cancer Genome Profiling Tests in Japan and Prospects for Liquid Biopsy.日本基于新一代测序的癌症基因组分析检测的现状及液体活检的前景
Life (Basel). 2021 Aug 6;11(8):796. doi: 10.3390/life11080796.
Arch Pathol Lab Med. 2020 May;144(5):545-563. doi: 10.5858/arpa.2019-0904-SA. Epub 2020 Jan 13.
4
RET rearrangements are actionable alterations in breast cancer.RET 重排是乳腺癌的一种可靶向改变。
Nat Commun. 2018 Nov 16;9(1):4821. doi: 10.1038/s41467-018-07341-4.
5
Overall survival analysis of EXAM, a phase III trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma.EXAM的总生存分析，一项卡博替尼用于放射性进展性甲状腺髓样癌患者的III期试验。
Ann Oncol. 2017 Nov 1;28(11):2813-2819. doi: 10.1093/annonc/mdx479.
6
Sorafenib for the treatment of breast cancer.索拉非尼用于治疗乳腺癌。
Expert Opin Pharmacother. 2017 Apr;18(6):621-630. doi: 10.1080/14656566.2017.1309024. Epub 2017 Apr 7.
7
Cabozantinib in patients with advanced RET-rearranged non-small-cell lung cancer: an open-label, single-centre, phase 2, single-arm trial.卡博替尼用于晚期RET重排非小细胞肺癌患者：一项开放标签、单中心、2期、单臂试验。
Lancet Oncol. 2016 Dec;17(12):1653-1660. doi: 10.1016/S1470-2045(16)30562-9. Epub 2016 Nov 4.
8
The landscape and therapeutic relevance of cancer-associated transcript fusions.癌症相关转录本融合的格局及其治疗相关性。
Oncogene. 2015 Sep 10;34(37):4845-54. doi: 10.1038/onc.2014.406. Epub 2014 Dec 15.
9
Integrated genomic characterization of papillary thyroid carcinoma.甲状腺乳头状癌的综合基因组特征分析
Cell. 2014 Oct 23;159(3):676-90. doi: 10.1016/j.cell.2014.09.050.
10
The landscape of kinase fusions in cancer.癌症中激酶融合的情况
Nat Commun. 2014 Sep 10;5:4846. doi: 10.1038/ncomms5846.